The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

The future of skin cancer treatment looks even more promising. Advances in artificial intelligence (AI) are revolutionizing ...

Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...

“It took us a few minutes to accept that this pile of rubble was our home,” said Islam Dahliz, whose family was ordered by Israeli forces to evacuate Rafah in May. By Vivian Yee and Bilal ...

Trump Asserts a Muscular Vision of Presidential Power as He Takes Over In a flurry of executive actions, President Trump revived disputed claims of broad presidential authority from his first term ...

Mimis Domazos, the Greek soccer legend and a Panathinaikos icon is hospitalized in critical condition after suffering a cardiac arrest on Wednesday, January 22, a statement released by the hospital ...